Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» obesity
obesity
Eli Lilly infiltrates anti-obesity market as Phase III trial for retatrutide begins
Clinical Trials Arena
Thu, 08/31/23 - 06:02 pm
Eli Lilly
retatrutide
clinical trials
NASH
obesity
diabetes
type 2 diabetes
Novo Bolsters Obesity Pipeline with Potential $500M Embark Biotech Buy
BioSpace
Wed, 08/30/23 - 11:22 am
Novo Nordisk
Embark Biotech
obesity
M&A
Boehringer preps phase 3 for dual-action obesity drug
Pharmaphorum
Thu, 08/17/23 - 09:54 am
Boehringer Ingelheim
clinical trials
obesity
survodutide
Obesity, diabetes drugs push Novo Nordisk and Eli Lilly to front of pharma's growth pack in Q2
Fierce Pharma
Wed, 08/16/23 - 10:05 am
Novo Nordisk
Eli Lilly
obesity
diabetes
earnings
Novo Nordisk bets $1.1B on Canadian biotech buyout, adding an old approach to obesity pipeline
Fierce Biotech
Thu, 08/10/23 - 11:41 am
Novo Nordisk
M&A
obesity
Inversago
In the era of blockbuster obesity drugs, a personalized approach could boost outcomes
Pharma Voice
Wed, 08/9/23 - 10:14 am
obesity
Phenomix
Novo Nordisk
Ozempic
Wegovy
Novo Nordisk posts 'best-case scenario' cardio outcomes data for star obesity drug Wegovy
Fierce Pharma
Tue, 08/8/23 - 11:25 am
Novo Nordisk
Wegovy
clinical trials
cardiovascular disease
obesity
10 clinical trials to watch in the second half of 2023
BioPharma Dive
Mon, 08/7/23 - 10:32 am
clinical trials
Sarepta Therapeutics
DMD
Elevidys
Bridge Bio
ATTR-CM
acoramidis
Sanofi
Merck KGaA
MS
tolebrutinib
Pfizer
obesity
danuglipron
Novo Nordisk
Ozempic
Verve Therapeutics
heterozygous familial hypercholesterolemia
Roche
lung cancer
tiragolumab
Vertex Pharmaceutical
VS-548
pain
JNJ
Bristol Myers Squibb
Lilly's obesity drug leads to about 26% weight loss in new studies
Yahoo/Reuters
Thu, 07/27/23 - 11:41 am
Eli Lilly
obesity
clinical trials
Mounjaro
Eli Lilly's Mounjaro shortage worsens ahead of potential obesity FDA approval
Fierce Pharma
Wed, 07/26/23 - 11:26 am
Eli Lilly
Mounjaro
obesity
weight loss
drug shortages
Novo Nordisk, Eli Lilly and Boehringer Ingelheim back bill to bring obesity drug coverage to Medicare
Fierce Pharma
Thu, 07/20/23 - 09:42 pm
Novo Nordisk
Eli Lilly
Boehringer Ingelheim
obesity
Novartis axes secretive obesity program after high-risk, high-reward bet fails
Fierce Biotech
Tue, 07/18/23 - 11:41 am
Novartis
obesity
pancreatic cancer
Hungry for more, Lilly tops off weight loss pipeline with $1.9B deal to acquire Versanis
Fierce Biotech
Fri, 07/14/23 - 10:10 am
Eli Lilly
M&A
obesity
Versanis
bimagrumab
Pharma finds a way to gain weight
EP Vantage
Thu, 07/13/23 - 09:49 am
obesity
Eli Lilly
Novo Nordisk
Wegovy
Mounjaro
Why Novo Nordisk Stock Sank on Tuesday
Motley Fool
Tue, 07/11/23 - 11:23 pm
Novo Nordisk
obesity
Wegovy
Ozempic Sales Are Soaring -- Here's Why They Could Go Even Higher
Motley Fool
Thu, 07/6/23 - 11:17 am
Novo Nordisk
Ozempic
obesity
diabetes
weight loss
addiction
Pfizer Just Canned One of Its Ozempic Killers. What's Next?
Motley Fool
Mon, 07/3/23 - 10:37 am
Pfizer
obesity
lotiglipron
danuglipron
Novo Nordisk
Eli Lilly
Ozempic
Mounjaro
Obesity: Six trials to watch over the next 12 months
Clinical Trials Arena
Fri, 06/30/23 - 11:45 am
obesity
clinical trials
Novo Nordisk
Altimmune
Innovent Biologics
Pfizer
Shionogi
Tonix
semaglutide
oxytocin
permvidutide
mazdutide
danuglipron
ADA 2023 – Lilly unveils its triple threat
EP Vantage
Wed, 06/28/23 - 09:57 am
Eli Lilly
Novo Nordisk
retatrutide
Wegovy
Mounjaro
obesity
clinical trials
Lilly links oral obesity drug to 15% weight loss, setting bar for Pfizer in blockbuster battle
Fierce Biotech
Mon, 06/26/23 - 10:00 am
Eli Lilly
obesity
orforglipron
Pfizer
Novo Nordisk
Mounjaro
Pages
« first
‹ previous
…
5
6
7
8
9
10
11
12
13
…
next ›
last »